MedImmune, LLC-Product Pipeline Review-2015

MedImmune, LLC-Product Pipeline Review-2015

  • Products Id :- GMDHC07354CDB
  • |
  • Pages: 142
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

MedImmune, LLC-Product Pipeline Review-2015


Global Markets Direct's, 'MedImmune, LLC-Product Pipeline Review-2015', provides an overview of the MedImmune, LLC's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of MedImmune, LLC's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of MedImmune, LLC including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of MedImmune, LLC's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the MedImmune, LLC's pipeline products

Reasons To Buy

Evaluate MedImmune, LLC's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of MedImmune, LLC in its therapy areas of focus

Identify new drug targets and therapeutic classes in the MedImmune, LLC's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of MedImmune, LLC and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of MedImmune, LLC

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of MedImmune, LLC and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

MedImmune, LLC Snapshot 6

MedImmune, LLC Overview 6

Key Information 6

Key Facts 6

MedImmune, LLC-Research and Development Overview 7

Key Therapeutic Areas 7

MedImmune, LLC-Pipeline Review 13

Pipeline Products by Stage of Development 13

Pipeline Products-Monotherapy 14

Pipeline Products-Combination Treatment Modalities 15

Pipeline Products-Partnered Products 16

Pipeline Products-Out-Licensed Products 18

MedImmune, LLC-Pipeline Products Glance 20

MedImmune, LLC-Late Stage Pipeline Products 20

MedImmune, LLC-Clinical Stage Pipeline Products 21

MedImmune, LLC-Early Stage Pipeline Products 25

MedImmune, LLC-Unknown Stage Pipeline Products 28

MedImmune, LLC-Drug Profiles 29

anifrolumab 29

benralizumab 30

durvalumab 32

durvalumab + tremelimumab 35

moxetumomab pasudotox 37

tralokinumab 39

MEDI-551 41

tremelimumab 43

dusigitumab 45

mavrilimumab 47

MEDI-4893 49

MEDI-8897 51

sifalimumab 52

MEDI-0382 54

MEDI-0680 55

MEDI-6469 56

SG-2000 58

AMG-211 60

AMP-110 62

AMP-224 64

durvalumab + MEDI-0680 66

MEDI-0562 67

MEDI-0639 69

MEDI-1814 70

MEDI-3617 71

MEDI-3902 72

MEDI-4920 73

MEDI-550 74

MEDI-6012 76

MEDI-6383 78

MEDI-7510 79

MEDI-7836 81

MEDI-8111 82

MEDI-8852 83

Oncolytic Virus to Activate IFN-b for Hepatocellular Carcinoma and Head And Neck Cancer Squamous Cell Carcinoma 84

respiratory syncytial virus vaccine 1 86

respiratory syncytial virus vaccine 2 87

tremelimumab + MEDI-3617 88

MEDI-5117 89

264-RAD 90

Antibody to Inhibit ILT7 for Systemic Lupus Erythematosus 91

Biologics for Acute Coronary Syndrome 92

EVT-770 93

MEDI-5304 94

Monoclonal Antibody Conjugates to Inhibit DNA Synthesis for Solid and Hematological Tumors 95

Monoclonal Antibody to Inhibit OX40 Ligand for Asthma 96

PRO-391 97

SG-2285 98

V-2L2MD 99

ALM 100

Monoclonal Antibodies for Cancer 101

Monoclonal Antibody for Undisclosed Indication 102

Recombinant Proteins for Cancer 103

MedImmune, LLC-Pipeline Analysis 104

MedImmune, LLC-Pipeline Products by Target 104

MedImmune, LLC-Pipeline Products by Route of Administration 107

MedImmune, LLC-Pipeline Products by Molecule Type 108

MedImmune, LLC-Pipeline Products by Mechanism of Action 109

MedImmune, LLC-Recent Pipeline Updates 112

MedImmune, LLC-Dormant Projects 126

MedImmune, LLC-Discontinued Pipeline Products 128

Discontinued Pipeline Product Profiles 128

MedImmune, LLC-Company Statement 132

MedImmune, LLC-Locations And Subsidiaries 134

Head Office 134

Other Locations & Subsidiaries 134

MedImmune, LLC-Key Manufacturing Facilities 136

Appendix 137

Methodology 137

Coverage 137

Secondary Research 137

Primary Research 137

Expert Panel Validation 137

Contact Us 137

Disclaimer 138

List of Tables

MedImmune, LLC, Key Information 10

MedImmune, LLC, Key Facts 10

MedImmune, LLC-Pipeline by Indication, 2015 12

MedImmune, LLC-Pipeline by Stage of Development, 2015 17

MedImmune, LLC-Monotherapy Products in Pipeline, 2015 18

MedImmune, LLC-Combination Treatment Modalities in Pipeline, 2015 19

MedImmune, LLC-Partnered Products in Pipeline, 2015 20

MedImmune, LLC-Partnered Products/ Combination Treatment Modalities, 2015 21

MedImmune, LLC-Out-Licensed Products in Pipeline, 2015 22

MedImmune, LLC-Out-Licensed Products/ Combination Treatment Modalities, 2015 23

MedImmune, LLC-Phase III, 2015 24

MedImmune, LLC-Phase II, 2015 25

MedImmune, LLC-Phase I, 2015 26

MedImmune, LLC-Phase 0, 2015 28

MedImmune, LLC-IND/CTA Filed, 2015 29

MedImmune, LLC-Preclinical, 2015 30

MedImmune, LLC-Discovery, 2015 31

MedImmune, LLC-Unknown, 2015 32

MedImmune, LLC-Pipeline by Target, 2015 108

MedImmune, LLC-Pipeline by Route of Administration, 2015 111

MedImmune, LLC-Pipeline by Molecule Type, 2015 112

MedImmune, LLC-Pipeline Products by Mechanism of Action, 2015 113

MedImmune, LLC-Recent Pipeline Updates, 2015 116

MedImmune, LLC-Dormant Developmental Projects,2015 130

MedImmune, LLC-Discontinued Pipeline Products, 2015 132

MedImmune, LLC, Other Locations 138

MedImmune, LLC, Subsidiaries 139

MedImmune, LLC, Key Manufacturing Facilities 140

List of Figures

MedImmune, LLC-Pipeline by Top 10 Indication, 2015 12

MedImmune, LLC-Pipeline by Stage of Development, 2015 17

MedImmune, LLC-Monotherapy Products in Pipeline, 2015 18

MedImmune, LLC-Combination Treatment Modalities in Pipeline, 2015 19

MedImmune, LLC-Partnered Products in Pipeline, 2015 20

MedImmune, LLC-Out-Licensed Products in Pipeline, 2015 22

MedImmune, LLC-Pipeline by Top 10 Target, 2015 108

MedImmune, LLC-Pipeline by Top 10 Route of Administration, 2015 111

MedImmune, LLC-Pipeline by Top 10 Molecule Type, 2015 112

MedImmune, LLC-Pipeline Products by Top 10 Mechanism of Action, 2015 113

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of MedImmune, LLC; MedImmune, LLC - Key Therapeutics; MedImmune, LLC - Pipeline Overview and Promising Molecules; MedImmune, LLC - News; MedImmune, LLC - Latest Updates; MedImmune, LLC - Pipeline; MedImmune, LLC - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 101175
Site License
USD 3000 INR 202350
Corporate User License
USD 4500 INR 303525



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]